Without action, the best intentions in the world are nothing more than that: intentions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $ETST Earth Science Tech, Inc. (ETST) Takes Advantage of Farm Bill Opportunities, Signs New Chief Sales Officer to Distribute CBD Products Through Nationwide Chain Retailers
Earth Science Tech, Inc. (ETST) Takes Advantage of Farm Bill Opportunities, Signs New Chief Sales Officer to Distribute CBD Products Through Nationwide Chain Retailers
DORAL, Florida, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it is taking advantage of the new Farm Bill, which is set to legalize hemp cultivation and hemp-derived CBD and other products in the United States, by signing David Barbash as its chief sales officer beginning in 2019. Mr. Barbash is a results-driven sales and marketing professional with more than 20 years of new business development to his credit and is a proven negotiator, manager and motivator.
As has been widely publicized, the 2018 Farm Bill, being signed soon, removes hemp (including hemp-derived cannabinoids containing less than 0.3% THC) from the Controlled Substances Act and transfers oversight of these products from the Drug Enforcement Agency to the U.S. Department of Agriculture. The new classification will allow domestic banks to now accept and process transactions related to hemp-derived cannabinoid-based products and opens doors to commercialize these products in the mass market. New Frontier cannabis market data projects the American CBD market will reach $2.3 billion in revenues by 2022.
To further take advantage of and capitalize on this amazing new opportunity, the Company has transitioned Jill Buzan, ETST’s current chief sales officer, to direct the Company’s sales in Florida while Mr. Barbash steps in as the new chief sales officer beginning in 2019. Mr. Barbash will begin distributing ETST’s cannabinoid products through his nationwide small, medium and large chain retail accounts.
Mr. Barbash brings to the Company more than 25 years of natural products industry experience in both the U.S. and U.K. markets, having previously worked with niche forward-thinking companies like Health From The Sun/Arkopharma, Pure Essence Labs, and Harmonic Innerprizes. He brings extensive international experience and a high level of enthusiasm to his new role at ETST.
“It’s an incredibly exciting time at ETST, and I am very thankful to be heading up the team that is going to lead the way in the cannabinoid sector when it comes to product efficacy, purity and clinically backed effectiveness,” Mr. Barbash states. “In 2019, through increased distribution, an expanded sales force, further emphasis on education and projected record sales, we hope to provide a banner year for our customers, future customers and, ultimately, the consumer.”
Nickolas S. Tabraue, president, director and chairman of ETST, states, “We are thrilled to add David to our team, and we look forward to an exciting year as he steps in as ETST’s new chief sales officer. His expertise and enthusiasm will be tremendous assets as we ride the wave opportunity afforded by the legalization of hemp cultivation and hemp-derived CBD in the United States.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Takes Advantage of Farm Bill Opportunities, Signs New Chief Sales Officer to Distribute CBD Products Through Nationwide Chain Retailers
Earth Science Tech, Inc. (ETST) Takes Advantage of Farm Bill Opportunities, Signs New Chief Sales Officer to Distribute CBD Products Through Nationwide Chain Retailers
DORAL, Florida, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it is taking advantage of the new Farm Bill, which is set to legalize hemp cultivation and hemp-derived CBD and other products in the United States, by signing David Barbash as its chief sales officer beginning in 2019. Mr. Barbash is a results-driven sales and marketing professional with more than 20 years of new business development to his credit and is a proven negotiator, manager and motivator.
As has been widely publicized, the 2018 Farm Bill, being signed soon, removes hemp (including hemp-derived cannabinoids containing less than 0.3% THC) from the Controlled Substances Act and transfers oversight of these products from the Drug Enforcement Agency to the U.S. Department of Agriculture. The new classification will allow domestic banks to now accept and process transactions related to hemp-derived cannabinoid-based products and opens doors to commercialize these products in the mass market. New Frontier cannabis market data projects the American CBD market will reach $2.3 billion in revenues by 2022.
To further take advantage of and capitalize on this amazing new opportunity, the Company has transitioned Jill Buzan, ETST’s current chief sales officer, to direct the Company’s sales in Florida while Mr. Barbash steps in as the new chief sales officer beginning in 2019. Mr. Barbash will begin distributing ETST’s cannabinoid products through his nationwide small, medium and large chain retail accounts.
Mr. Barbash brings to the Company more than 25 years of natural products industry experience in both the U.S. and U.K. markets, having previously worked with niche forward-thinking companies like Health From The Sun/Arkopharma, Pure Essence Labs, and Harmonic Innerprizes. He brings extensive international experience and a high level of enthusiasm to his new role at ETST.
“It’s an incredibly exciting time at ETST, and I am very thankful to be heading up the team that is going to lead the way in the cannabinoid sector when it comes to product efficacy, purity and clinically backed effectiveness,” Mr. Barbash states. “In 2019, through increased distribution, an expanded sales force, further emphasis on education and projected record sales, we hope to provide a banner year for our customers, future customers and, ultimately, the consumer.”
Nickolas S. Tabraue, president, director and chairman of ETST, states, “We are thrilled to add David to our team, and we look forward to an exciting year as he steps in as ETST’s new chief sales officer. His expertise and enthusiasm will be tremendous assets as we ride the wave opportunity afforded by the legalization of hemp cultivation and hemp-derived CBD in the United States.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Global Medical Device Market Anticipated to Surpass $400 Billion by 2023
Global Medical Device Market Anticipated to Surpass $400 Billion by 2023
December 18, 2018
Palm Beach, FL – (December 18, 2018) – With long life expectancy and emerging economies’ increasing expenditure on healthcare, there is an increased and growing demand for technologically superior medical devices. According to ResearchAndMarkets.com, the global medical device market is expected to reach an estimated $409.5 Billion by 2023, and it is forecast to grow at a CAGR of 4.5% from 2018 to 2023. Major factors for the growth in the industry are healthcare expenditure, technological development, aging population, and chronic diseases. The medical technology industry (commonly referred to as medical devices) consists of instruments, devices apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Active biotech, medical and pharma companies in the markets this week include Earth Science Tech, Inc. (OTCQB:ETST), Evofem Biosciences, Inc. (NASDAQ:EVFM), Novavax, Inc. (NASDAQ:NVAX), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN).
Earth Science Tech, Inc. (OTC:ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. Read this and more news for ETST at https://www.financialnewsmedia.com/news-etst
Other recent developments and happenings in the biotech industry include:
Evofem Biosciences, Inc. (NASDAQ:EVFM) this week announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint. AMPOWER assessed the efficacy, safety and subject satisfaction with Amphora in approximately 1,400 healthy women aged 18-35 years at 112 centers in the U.S. The primary endpoint of the study was the pregnancy rate over seven cycles of use (one cycle = 21-35 days) as assessed by the Kaplan-Meier statistical method. Top-line data analysis demonstrates a cumulative pregnancy rate of 14.0% over seven cycles of use (95% CI 10.0, 18.0). This corresponds to an 86.0% efficacy rate (referred to as typical use), which meets the pre-determined endpoint of this clinical trial. In women who correctly used Amphora per study protocol, the cumulative pregnancy rate was 1.3% over seven cycles of use (95% CI 0.4, 2.1). This corresponds to a 98.7% efficacy rate. The results demonstrate that when Amphora is used as directed, the efficacy in which women can have confidence is similar to other frequently used contraceptive methods.
Novavax, Inc. (NASDAQ:NVAX) recently announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important management promotions; Jill and Biegie are vital parts of a seasoned executive team striving to accomplish our near and long-term corporate objectives,” said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “Jill has been working with me and the senior leadership team to hire, develop and support employees of this company, which is consistently being recognized as one of the best in the biopharmaceutical industry. Biegie has been leading Novavax’ efforts to preserve, protect and support our robust IT infrastructure, an important function given our needs around the ongoing management of enourmous amounts of data with complex information system tools.”
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) this week announced positive topline results from the Phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who suffer from either chronic or episodic migraine, patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days versus placebo (-0.6 days) over the 12 week assessment period, for both monthly (-4.1 days, p<0.0001) and quarterly (-3.7 days, p<0.0001) dosing regimens. In addition, patients treated with fremanezumab experienced significant improvement compared to placebo on all secondary endpoints for both quarterly and monthly dosing regimens. There were no safety signals detected in the study.
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced this week that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. Currently, tPA – a thrombolytic used to break down blood clots in patients suffering from ischemic stroke – is the only FDA-approved therapeutic stroke treatment. Worldwide, stroke is the second leading cause of death and is responsible for an estimated 6.2 million deaths per year. The granting of Diffusion’s patent follows the recent news that the Company received FDA approval to enroll patients in an ambulance-based Phase 2 clinical trial testing TSC for the treatment of both ischemic and hemorrhagic stroke.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST Global Medical Device Market Anticipated to Surpass $400 Billion by 2023
Global Medical Device Market Anticipated to Surpass $400 Billion by 2023
December 18, 2018
Palm Beach, FL – (December 18, 2018) – With long life expectancy and emerging economies’ increasing expenditure on healthcare, there is an increased and growing demand for technologically superior medical devices. According to ResearchAndMarkets.com, the global medical device market is expected to reach an estimated $409.5 Billion by 2023, and it is forecast to grow at a CAGR of 4.5% from 2018 to 2023. Major factors for the growth in the industry are healthcare expenditure, technological development, aging population, and chronic diseases. The medical technology industry (commonly referred to as medical devices) consists of instruments, devices apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Active biotech, medical and pharma companies in the markets this week include Earth Science Tech, Inc. (OTCQB:ETST), Evofem Biosciences, Inc. (NASDAQ:EVFM), Novavax, Inc. (NASDAQ:NVAX), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN).
Earth Science Tech, Inc. (OTC:ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. Read this and more news for ETST at https://www.financialnewsmedia.com/news-etst
Other recent developments and happenings in the biotech industry include:
Evofem Biosciences, Inc. (NASDAQ:EVFM) this week announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint. AMPOWER assessed the efficacy, safety and subject satisfaction with Amphora in approximately 1,400 healthy women aged 18-35 years at 112 centers in the U.S. The primary endpoint of the study was the pregnancy rate over seven cycles of use (one cycle = 21-35 days) as assessed by the Kaplan-Meier statistical method. Top-line data analysis demonstrates a cumulative pregnancy rate of 14.0% over seven cycles of use (95% CI 10.0, 18.0). This corresponds to an 86.0% efficacy rate (referred to as typical use), which meets the pre-determined endpoint of this clinical trial. In women who correctly used Amphora per study protocol, the cumulative pregnancy rate was 1.3% over seven cycles of use (95% CI 0.4, 2.1). This corresponds to a 98.7% efficacy rate. The results demonstrate that when Amphora is used as directed, the efficacy in which women can have confidence is similar to other frequently used contraceptive methods.
Novavax, Inc. (NASDAQ:NVAX) recently announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important management promotions; Jill and Biegie are vital parts of a seasoned executive team striving to accomplish our near and long-term corporate objectives,” said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “Jill has been working with me and the senior leadership team to hire, develop and support employees of this company, which is consistently being recognized as one of the best in the biopharmaceutical industry. Biegie has been leading Novavax’ efforts to preserve, protect and support our robust IT infrastructure, an important function given our needs around the ongoing management of enourmous amounts of data with complex information system tools.”
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) this week announced positive topline results from the Phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who suffer from either chronic or episodic migraine, patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days versus placebo (-0.6 days) over the 12 week assessment period, for both monthly (-4.1 days, p<0.0001) and quarterly (-3.7 days, p<0.0001) dosing regimens. In addition, patients treated with fremanezumab experienced significant improvement compared to placebo on all secondary endpoints for both quarterly and monthly dosing regimens. There were no safety signals detected in the study.
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced this week that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. Currently, tPA – a thrombolytic used to break down blood clots in patients suffering from ischemic stroke – is the only FDA-approved therapeutic stroke treatment. Worldwide, stroke is the second leading cause of death and is responsible for an estimated 6.2 million deaths per year. The granting of Diffusion’s patent follows the recent news that the Company received FDA approval to enroll patients in an ambulance-based Phase 2 clinical trial testing TSC for the treatment of both ischemic and hemorrhagic stroke.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run and Early 2019 Launch of Hygee
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run and Early 2019 Launch of Hygee
Innovative biotechnology company Earth Science Tech (OTCQB: ETST) this morning announced that it has ordered the first commercial production run of Hygee, its new medical device for women that enables discreet, anonymous testing for sexually transmitted infections (“STIs”). According to the update, the official launch is scheduled for early 2019, and initial marketing will target North America, South America, Asia and Africa. The company will package Hygee in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach a wide consumer audience. “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee,” ETST CEO and Chief Science Officer Dr. Michel Aube stated in the news release. “Through intentional design, Hygee is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee is dedicated to this area of women’s health.”
To view the full press release, visit: http://nnw.fm/ptsF0
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com.
More from NetworkNewsBreaks
NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Appoints Chief Financial Officer for its CBD Biotech Subsidiary
NetworkNewsBreaks – Sunniva Inc.’s (CSE: SNN) (OTCQX: SNNVF) NHS Subsidiary Partners with HelloMD to Expand Patient Reach, Offer Enhanced Medical Cannabis Services
NetworkNewsBreaks – DPW Holdings, Inc. (NYSE American: DPW) Board of Directors Approves Pursuit of DPW Technology Group IPO
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run and Early 2019 Launch of Hygee
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run and Early 2019 Launch of Hygee
Innovative biotechnology company Earth Science Tech (OTCQB: ETST) this morning announced that it has ordered the first commercial production run of Hygee, its new medical device for women that enables discreet, anonymous testing for sexually transmitted infections (“STIs”). According to the update, the official launch is scheduled for early 2019, and initial marketing will target North America, South America, Asia and Africa. The company will package Hygee in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach a wide consumer audience. “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee,” ETST CEO and Chief Science Officer Dr. Michel Aube stated in the news release. “Through intentional design, Hygee is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee is dedicated to this area of women’s health.”
To view the full press release, visit: http://nnw.fm/ptsF0
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com.
More from NetworkNewsBreaks
NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Appoints Chief Financial Officer for its CBD Biotech Subsidiary
NetworkNewsBreaks – Sunniva Inc.’s (CSE: SNN) (OTCQX: SNNVF) NHS Subsidiary Partners with HelloMD to Expand Patient Reach, Offer Enhanced Medical Cannabis Services
NetworkNewsBreaks – DPW Holdings, Inc. (NYSE American: DPW) Board of Directors Approves Pursuit of DPW Technology Group IPO
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run of Hygee(TM) Kits
Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run of Hygee™ Kits
Launch of new medical device to fight STIs slated for early 2019
DORAL, Florida, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin structure of the device and the stability of the specimen collected with Hygee™ ensures that it can be easily dispersed on all continents.
“We believe that ETST has developed the best tool on the market to fight STIs, which will provide an exceptional service to women who use Hygee™,” states Nickolas S. Tabraue, the company’s president, director, and chairman. “The production of the first batch of Hygee™ is very exciting. Our team believed in the success of Hygee™ from the first day we acquired it. Now, we will do everything possible to spread this fabulous medical device everywhere on the planet to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run of Hygee(TM) Kits
Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run of Hygee™ Kits
Launch of new medical device to fight STIs slated for early 2019
DORAL, Florida, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin structure of the device and the stability of the specimen collected with Hygee™ ensures that it can be easily dispersed on all continents.
“We believe that ETST has developed the best tool on the market to fight STIs, which will provide an exceptional service to women who use Hygee™,” states Nickolas S. Tabraue, the company’s president, director, and chairman. “The production of the first batch of Hygee™ is very exciting. Our team believed in the success of Hygee™ from the first day we acquired it. Now, we will do everything possible to spread this fabulous medical device everywhere on the planet to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Reports Positive Results from Hygee(TM) Pre-launch Testing
Earth Science Tech, Inc. (ETST) Reports Positive Results from Hygee™ Pre-launch Testing
DORAL, Florida, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces successful in vitro analyses of gynecological samples collected using its new Hygee™ medical device.
Hygee™ is a discreet, wearable medical device that enables a woman to anonymously test for sexually transmitted infections (STIs). As previously announced, samples collected by the Hygee™ device are tested by Procréa. In pre-launch testing at the labs, molecular diagnostic assays successfully identified the presence of Chlamydia in test subjects, confirming earlier testing results in a cohort of more than 500 women.
ETST’s President, Director and Chairman Nickolas S. Tabraue states, “We are pleased to announce positive testing in the pre-launch phase of Hygee™, and would like to thank our carefully selected partners, Procréa, for a job well done. They are a part of the guarantee of our success.”
ETST is on track to launch Hygee™ in early 2019. The Company plans to market the product through its established distribution channels, mentioned in November, thanks to Dermagate’s ISO 13485:2013 certification.
“Hygee™ is an incredible innovation, and we have partners from many countries waiting to market the device,” stated ETST CEO and Chief Scientific Officer Dr. Michel Aubé. “This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
In its first iteration, Hygee™ will be marketed as an at-home test for chlamydia; however, R&D efforts currently underway indicate that Hygee™ will soon be certified for gonorrhea testing as well.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Reports Positive Results from Hygee(TM) Pre-launch Testing
Earth Science Tech, Inc. (ETST) Reports Positive Results from Hygee™ Pre-launch Testing
DORAL, Florida, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces successful in vitro analyses of gynecological samples collected using its new Hygee™ medical device.
Hygee™ is a discreet, wearable medical device that enables a woman to anonymously test for sexually transmitted infections (STIs). As previously announced, samples collected by the Hygee™ device are tested by Procréa. In pre-launch testing at the labs, molecular diagnostic assays successfully identified the presence of Chlamydia in test subjects, confirming earlier testing results in a cohort of more than 500 women.
ETST’s President, Director and Chairman Nickolas S. Tabraue states, “We are pleased to announce positive testing in the pre-launch phase of Hygee™, and would like to thank our carefully selected partners, Procréa, for a job well done. They are a part of the guarantee of our success.”
ETST is on track to launch Hygee™ in early 2019. The Company plans to market the product through its established distribution channels, mentioned in November, thanks to Dermagate’s ISO 13485:2013 certification.
“Hygee™ is an incredible innovation, and we have partners from many countries waiting to market the device,” stated ETST CEO and Chief Scientific Officer Dr. Michel Aubé. “This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
In its first iteration, Hygee™ will be marketed as an at-home test for chlamydia; however, R&D efforts currently underway indicate that Hygee™ will soon be certified for gonorrhea testing as well.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $PYTG Pyramidion Technology Group, Inc. (OTC: PYTG) Subsidiary NxGen Brands Enters Into an Agreement to Provide Custom-designed CBD-product Formulations to Emergent Health
Pyramidion Technology Group, Inc. (OTC: PYTG) Subsidiary NxGen Brands Enters Into an Agreement to Provide Custom-designed CBD-product Formulations to Emergent Health
WESTON, Florida, December 13, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc. (OTCPINK: PYTG), owner of LeafyWell.com (LeafyWell.com), established CBD-product (Cannabidiol) manufacturer and distributor, and NxGen Brands, specializing in the sales and marketing of innovative healthcare products and service solutions, today announced the finalization of a contractual agreement to provide custom CBD-product formulations to Emergent Health, Corp.
NxGen Brands, a subsidiary of PYTG, is slated to launch specialized formulations for Emergent Health, LLC including the first product of its kind for both companies consisting of a propriety formula designed to aid in sleep, anxiety, and mood. The composite of these ingredients is manufactured to function in combination with each other to provide relief of nervousness and anxiety, and to facilitate improved sleep.
CEO of PYTG, Carlos Hurtado, when asked to summarize their relationship with Emergent Health, stated, "We are purely ecstatic to be working with Emergent Health and to be providing our product and services to a company with their level of reputation. This company (Emergent Health) is, in my opinion, at the forefront of both maintaining tradition and innovation in the supplement industry. They appear to have an incredibly loyal, and growing, client base having been cultivated over years and our working with them on providing specific profiles puts us all in the lead. I would like to give credit to our advisory board, on which serve multiple practicing physicians, for working on the precise profile of this custom product. With their knowledge, we are able to design, create, manufacture, and distribute such products as these custom-profile, CBD, and multiple ingredient-based products."
Emergent Health Corp. specializes in the development and sales of a wide range of health and wellness supplements including nutraceuticals, Phyto-nutritionals, and regenerative medicines. Their product line includes 'Vita-Stim' which designed to enhance the immune system and nourish stem cells; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and other products designed to reduce facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally.
"We welcome opportunities to work with existing companies and apply our expertise in product design and custom formulations. We anticipate many more of these types of custom products and we feel that the market can benefit by our formulation and production abilities, thereby meeting consumer demands," explains Carlos Hurtado, CEO of PYTG. Currently, PYTG owns NxGen Brands, LLC and LeafyWell, LLC (LeafyWell.com) specializing in CBD-containing products such as tinctures, creams, lotions, edible gummy candies, as well as the newest of the line-up: a full and complete product line of pet treats. For more information on LeafyWell, visit LeafyWell.com.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
News: $PYTG Pyramidion Technology Group, Inc. (OTC: PYTG) Subsidiary NxGen Brands Enters Into an Agreement to Provide Custom-designed CBD-product Formulations to Emergent Health
Pyramidion Technology Group, Inc. (OTC: PYTG) Subsidiary NxGen Brands Enters Into an Agreement to Provide Custom-designed CBD-product Formulations to Emergent Health
WESTON, Florida, December 13, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc. (OTCPINK: PYTG), owner of LeafyWell.com (LeafyWell.com), established CBD-product (Cannabidiol) manufacturer and distributor, and NxGen Brands, specializing in the sales and marketing of innovative healthcare products and service solutions, today announced the finalization of a contractual agreement to provide custom CBD-product formulations to Emergent Health, Corp.
NxGen Brands, a subsidiary of PYTG, is slated to launch specialized formulations for Emergent Health, LLC including the first product of its kind for both companies consisting of a propriety formula designed to aid in sleep, anxiety, and mood. The composite of these ingredients is manufactured to function in combination with each other to provide relief of nervousness and anxiety, and to facilitate improved sleep.
CEO of PYTG, Carlos Hurtado, when asked to summarize their relationship with Emergent Health, stated, "We are purely ecstatic to be working with Emergent Health and to be providing our product and services to a company with their level of reputation. This company (Emergent Health) is, in my opinion, at the forefront of both maintaining tradition and innovation in the supplement industry. They appear to have an incredibly loyal, and growing, client base having been cultivated over years and our working with them on providing specific profiles puts us all in the lead. I would like to give credit to our advisory board, on which serve multiple practicing physicians, for working on the precise profile of this custom product. With their knowledge, we are able to design, create, manufacture, and distribute such products as these custom-profile, CBD, and multiple ingredient-based products."
Emergent Health Corp. specializes in the development and sales of a wide range of health and wellness supplements including nutraceuticals, Phyto-nutritionals, and regenerative medicines. Their product line includes 'Vita-Stim' which designed to enhance the immune system and nourish stem cells; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and other products designed to reduce facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally.
"We welcome opportunities to work with existing companies and apply our expertise in product design and custom formulations. We anticipate many more of these types of custom products and we feel that the market can benefit by our formulation and production abilities, thereby meeting consumer demands," explains Carlos Hurtado, CEO of PYTG. Currently, PYTG owns NxGen Brands, LLC and LeafyWell, LLC (LeafyWell.com) specializing in CBD-containing products such as tinctures, creams, lotions, edible gummy candies, as well as the newest of the line-up: a full and complete product line of pet treats. For more information on LeafyWell, visit LeafyWell.com.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Board Considering Dual Listing of Common Shares on Canadian Securities Exchange
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Board Considering Dual Listing of Common Shares on Canadian Securities Exchange
Innovative biotechnology company Earth Science Tech (OTCQB: ETST), which is now an “OTC reporting issuer” in the Canadian province of Québec, today announced that its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (“CSE”). According to the update, ETST intends to file an application with the CSE early next year, and listing is possible as early as Q3 2019 subject to certain regulatory approvals to allow the company to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space,” Earth Science President, Director and Chairman Nickolas S. Tabraue stated in the news release. “We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense.”
To view the full press release, visit: http://nnw.fm/iV26i
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com.
More from NetworkNewsBreaks
NetworkNewsBreaks – Marijuana Company of America Inc. (MCOA) Launches New hempSMART Website, Sales Platform
NetworkNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Announces Resignation of Natural Health Services Ltd. President
NetworkNewsBreaks – American Premium Water Corp. (HIPH) Enters Strategic Partnership with California-Based Growpacker
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Board Considering Dual Listing of Common Shares on Canadian Securities Exchange
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Board Considering Dual Listing of Common Shares on Canadian Securities Exchange
Innovative biotechnology company Earth Science Tech (OTCQB: ETST), which is now an “OTC reporting issuer” in the Canadian province of Québec, today announced that its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (“CSE”). According to the update, ETST intends to file an application with the CSE early next year, and listing is possible as early as Q3 2019 subject to certain regulatory approvals to allow the company to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space,” Earth Science President, Director and Chairman Nickolas S. Tabraue stated in the news release. “We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense.”
To view the full press release, visit: http://nnw.fm/iV26i
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com.
More from NetworkNewsBreaks
NetworkNewsBreaks – Marijuana Company of America Inc. (MCOA) Launches New hempSMART Website, Sales Platform
NetworkNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Announces Resignation of Natural Health Services Ltd. President
NetworkNewsBreaks – American Premium Water Corp. (HIPH) Enters Strategic Partnership with California-Based Growpacker
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST Emphasis on Developing Rare Cannabinoids-CBD Products Proving Valuable for Medicinal Marijuana Industry
Emphasis on Developing Rare Cannabinoids-CBD Products Proving Valuable for Medicinal Marijuana Industry
December 11, 2018
Palm Beach, FL – (December 11, 2018) – The CBD niche of the cannabis sector has been growing at a vociferous rate as CBD-based products rapidly gain popularity. While the potential uses of cannabinoids are vast and growing just about every day, Leading Cannabis companies are focusing on the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent and scalable production of a full spectrum of the roughly 100 cannabinoids, not just THC and CBD. As the cannabis in the U.S. remains federally illegal, the U.S. market opportunity is quite sizable, according to an Cowen analyst, with the current illicit market valued at around $40 billion to $50 billion. Sixty-six percent of survey respondents now support legalizing marijuana, according to the latest Gallup poll. That’s a record high and was the third consecutive year that support for legalization has increased to record levels. Active cannabis companies in the markets this week include Earth Science Tech, Inc. (OTC:ETST), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Pyxus International Inc. (NYSE:PYX), Aphria Inc. (NYSE:APHA) (TSX:APHA), MariMed Inc. (OTC:MRMD).
Earth Science Tech, Inc. (OTCQB:ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that as the Company is now an “OTC reporting issuer” in the Province of Québec, Canada, its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE).
Earth Science intends to file an application with the CSE in early 2019. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense,” states Earth Science president, director and Chairman Nickolas S. Tabraue. Read this and more news for ETST at http://www.financialnewsmedia.com/news-etst
Other recent developments in the cannabis industry include:
Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) came to a close Monday up slightly with a volume north of 19.9 million by the market close. Late last week, Cronos announced it has entered into a subscription agreement with Altria Group, Inc. (MO) pursuant to which Altria has agreed to make an approximately C$2.4 billion equity investment in Cronos Group (the “Transaction”) on a private placement basis in exchange for common shares in the capital of the Company (the “Shares”). Altria will also receive Warrants of Cronos Group (the “Warrants”), that if fully exercised, would provide the Company with an additional approximately C$1.4 billion of proceeds. The Shares issuable to Altria pursuant to the Subscription Agreement will result in Altria holding an approximately 45% ownership interest in Cronos Group (calculated on a non-diluted basis), exercise of the Warrants would result in incremental ownership of 10% for a total potential ownership position of 55%. This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry.
Pyxus International Inc. (NYSE:PYX) recently announced that its joint venture, Criticality, an integrated North Carolina-based industrial hemp company operating under North Carolina’s industrial hemp pilot program, has launched “Korent,” its new line of cannabidiol (CBD) oil products. Korent’s full-spectrum oil drops are available in Vanilla Mint and Grape flavors, in multiple sizes and concentrations. Flavors were custom designed for hemp products in partnership with Purilum, LLC, a leading flavor manufacturer and Pyxus-affiliated company. “Criticality’s science-based approach to the extraction, refinement and formulation of high-quality CBD products makes it well positioned in the market and presents a huge growth opportunity for both Criticality and Pyxus,” said Pieter Sikkel, Pyxus’ president, CEO and chairman of the board.
Aphria Inc. (NYSE:APHA) (TSX:APHA) recently announced its Board of Directors has appointed a special committee (the “Special Committee”) of independent directors to review the Company’s previously completed acquisition of LATAM Holdings Inc. (the “Acquisition”), which closed on September 27, 2018 , and confirm the Company’s belief that it conformed with all Company policies and generally accepted corporate governance practices. The Company’s Board reiterated its confidence in the process leading to the Acquisition, as well as in its Latin American operations and strategy. However, in the face of inaccurate and misleading accusations by certain short-sellers, whose sole interest is in profiting from a decline in the Company’s shares, it is undertaking a comprehensive review, led by a Special Committee of independent directors of these, and any other, allegations in the interest of protecting Aphria shareholders.
MariMed Inc. (OTCQB:MRMD) recently announced that Navy Capital Green Fund, LP, made a $14.725 million investment in MariMed in November 2018. Navy Capital is the first US-based Long/Short Equity Hedge Fund dedicated solely to the legal cannabis industry. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries. MariMed Inc. is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST Emphasis on Developing Rare Cannabinoids-CBD Products Proving Valuable for Medicinal Marijuana Industry
Emphasis on Developing Rare Cannabinoids-CBD Products Proving Valuable for Medicinal Marijuana Industry
December 11, 2018
Palm Beach, FL – (December 11, 2018) – The CBD niche of the cannabis sector has been growing at a vociferous rate as CBD-based products rapidly gain popularity. While the potential uses of cannabinoids are vast and growing just about every day, Leading Cannabis companies are focusing on the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent and scalable production of a full spectrum of the roughly 100 cannabinoids, not just THC and CBD. As the cannabis in the U.S. remains federally illegal, the U.S. market opportunity is quite sizable, according to an Cowen analyst, with the current illicit market valued at around $40 billion to $50 billion. Sixty-six percent of survey respondents now support legalizing marijuana, according to the latest Gallup poll. That’s a record high and was the third consecutive year that support for legalization has increased to record levels. Active cannabis companies in the markets this week include Earth Science Tech, Inc. (OTC:ETST), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Pyxus International Inc. (NYSE:PYX), Aphria Inc. (NYSE:APHA) (TSX:APHA), MariMed Inc. (OTC:MRMD).
Earth Science Tech, Inc. (OTCQB:ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that as the Company is now an “OTC reporting issuer” in the Province of Québec, Canada, its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE).
Earth Science intends to file an application with the CSE in early 2019. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense,” states Earth Science president, director and Chairman Nickolas S. Tabraue. Read this and more news for ETST at http://www.financialnewsmedia.com/news-etst
Other recent developments in the cannabis industry include:
Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) came to a close Monday up slightly with a volume north of 19.9 million by the market close. Late last week, Cronos announced it has entered into a subscription agreement with Altria Group, Inc. (MO) pursuant to which Altria has agreed to make an approximately C$2.4 billion equity investment in Cronos Group (the “Transaction”) on a private placement basis in exchange for common shares in the capital of the Company (the “Shares”). Altria will also receive Warrants of Cronos Group (the “Warrants”), that if fully exercised, would provide the Company with an additional approximately C$1.4 billion of proceeds. The Shares issuable to Altria pursuant to the Subscription Agreement will result in Altria holding an approximately 45% ownership interest in Cronos Group (calculated on a non-diluted basis), exercise of the Warrants would result in incremental ownership of 10% for a total potential ownership position of 55%. This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry.
Pyxus International Inc. (NYSE:PYX) recently announced that its joint venture, Criticality, an integrated North Carolina-based industrial hemp company operating under North Carolina’s industrial hemp pilot program, has launched “Korent,” its new line of cannabidiol (CBD) oil products. Korent’s full-spectrum oil drops are available in Vanilla Mint and Grape flavors, in multiple sizes and concentrations. Flavors were custom designed for hemp products in partnership with Purilum, LLC, a leading flavor manufacturer and Pyxus-affiliated company. “Criticality’s science-based approach to the extraction, refinement and formulation of high-quality CBD products makes it well positioned in the market and presents a huge growth opportunity for both Criticality and Pyxus,” said Pieter Sikkel, Pyxus’ president, CEO and chairman of the board.
Aphria Inc. (NYSE:APHA) (TSX:APHA) recently announced its Board of Directors has appointed a special committee (the “Special Committee”) of independent directors to review the Company’s previously completed acquisition of LATAM Holdings Inc. (the “Acquisition”), which closed on September 27, 2018 , and confirm the Company’s belief that it conformed with all Company policies and generally accepted corporate governance practices. The Company’s Board reiterated its confidence in the process leading to the Acquisition, as well as in its Latin American operations and strategy. However, in the face of inaccurate and misleading accusations by certain short-sellers, whose sole interest is in profiting from a decline in the Company’s shares, it is undertaking a comprehensive review, led by a Special Committee of independent directors of these, and any other, allegations in the interest of protecting Aphria shareholders.
MariMed Inc. (OTCQB:MRMD) recently announced that Navy Capital Green Fund, LP, made a $14.725 million investment in MariMed in November 2018. Navy Capital is the first US-based Long/Short Equity Hedge Fund dedicated solely to the legal cannabis industry. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries. MariMed Inc. is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST Earth Science Tech, Inc. (ETST) Considers Dual Listing of its Common Shares on the Canadian Securities Exchange (CSE)
Earth Science Tech, Inc. (ETST) Considers Dual Listing of its Common Shares on the Canadian Securities Exchange (CSE)
DORAL, Florida, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that as the Company is now an “OTC reporting issuer” in the Province of Québec, Canada, its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE).
Earth Science intends to file an application with the CSE in early 2019. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense,” states Earth Science president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Considers Dual Listing of its Common Shares on the Canadian Securities Exchange (CSE)
Earth Science Tech, Inc. (ETST) Considers Dual Listing of its Common Shares on the Canadian Securities Exchange (CSE)
DORAL, Florida, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that as the Company is now an “OTC reporting issuer” in the Province of Québec, Canada, its board of directors is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE).
Earth Science intends to file an application with the CSE in early 2019. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
“The Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the two exchanges we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our R&D operations conducted in Canada and our CEO residing in Canada, considering a listing on the CSE makes the most sense,” states Earth Science president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Announces Final Stage CBD/Propovit Throat Spray Formulation
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Announces Final Stage CBD/Propovit Throat Spray Formulation
Innovative biotechnology company Earth Science Tech (OTCQB: ETST) today announced that its new genuine CBD/Propovit throat spray formula is nearly market-ready. ETST collaborated with Bionatus in a strategic partnership to improve the product, resulting in a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp. “We are very excited to see this project in the final stage,” ETST CEO and Chief Science Officer Dr. Michel Aube stated in the news release. “We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation.”
To view the full press release, visit: http://nnw.fm/c9Hfe
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsBreaks
NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Reviews 2018 Revenues and Acquisition Successes on MoneyTV with Donald Baillargeon
NetworkNewsBreaks – American Premium Water Corp. (HIPH) Enters Partnership with Pain Management App and Platform
NetworkNewsBreaks – Altavoz Entertainment, Inc. (AVOZ) Issues Shareholder Update; Inks MOU with Nurish.Me, LLC
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Announces Final Stage CBD/Propovit Throat Spray Formulation
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Announces Final Stage CBD/Propovit Throat Spray Formulation
Innovative biotechnology company Earth Science Tech (OTCQB: ETST) today announced that its new genuine CBD/Propovit throat spray formula is nearly market-ready. ETST collaborated with Bionatus in a strategic partnership to improve the product, resulting in a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp. “We are very excited to see this project in the final stage,” ETST CEO and Chief Science Officer Dr. Michel Aube stated in the news release. “We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation.”
To view the full press release, visit: http://nnw.fm/c9Hfe
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsBreaks
NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Reviews 2018 Revenues and Acquisition Successes on MoneyTV with Donald Baillargeon
NetworkNewsBreaks – American Premium Water Corp. (HIPH) Enters Partnership with Pain Management App and Platform
NetworkNewsBreaks – Altavoz Entertainment, Inc. (AVOZ) Issues Shareholder Update; Inks MOU with Nurish.Me, LLC
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST Aggressive Development of Newest CBD Based Medicinal Products Occupying Large Share of Cannabis Industry
Aggressive Development of Newest CBD Based Medicinal Products Occupying Large Share of Cannabis Industry
December 7, 2018
Palm Beach, FL – (December 7, 2018) – The medicinal market within the overarching and extremely active cannabis industry has long been dominated by medicinal products based in cannabidiol, or CBD. CBD medicines have leveraged a compound from cannabis that does not create a high, but it is believed to have a wide variety of health benefits, including fighting inflammation and other everyday ailments. Greenwave Advisors estimates the CBD market as a whole could reach $3 billion in the United States within three years. Industry specialists believe that CBD could outstrip the rest of the cannabis sector in size in the next few years as a wide variety of end-use product potential is helping CBD based products gain mainstream use and global acceptance. Active cannabis companies in the markets this week include Earth Science Tech, Inc. (OTC:ETST), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED), Tilray Inc. (NASDAQ:TLRY), Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB), MedMen Enterprises Inc. (CSE:MMEN) (OTC:MMNFF).
Earth Science Tech, Inc. (OTCQB: ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that the new genuine CBD/Propovit throat spray formula developed through a strategic partnership with Bionatus is nearly market-ready.
As previously announced, ETST collaborated with Bionatus to improve the Propovit throat spray. The result is a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp.
Dr. Michel Aube, ETST’s CEO and chief science officer states, “We are very excited to see this project in the final stage. We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation. ”
The main active ingredient in Propovit is propolis, a compound derived from the Brazilian green bee and packed with strong antioxidants as well as potent anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties. The new formulation combines the effect of Propovit and ETST’s cannabinoids to help diminish the symptoms of throat infections via fine drops that spread the hemp oil widely onto the oromucosal part of the mouth.
ETST also plans to conduct clinical trials on the genuine CBD/Propovit formula to measure the combined effects of these two powerful components on throat infections. Read this and more news for ETST at https://www.financialnewsmedia.com/news-etst
Other recent developments in the cannabis industry include:
Canopy Growth Corporation (NYSE:CGC) (TSX:WEED) on Thursday announced it has finalized an all-cash transaction to acquire Storz & Bickel GmbH & Co. KG, related entities, and IP (collectively, “Storz & Bickel” or “S&B”) for a purchase price of up to approximately €145 million. With a 22-year track record of breakthrough innovations, Storz & Bickel is widely recognized as the global leader in vaporizer design and manufacturing. Based in Tuttlingen, Germany, Storz & Bickel are designers and manufacturers of medically approved vaporizers, most notably the Volcano® Medic and the Mighty® Medic. Storz & Bickel has spent the last two decades developing an automated and internationally certified factory, achieving ISO 13485 certification in 2009. The company has exported devices to 50 markets around the world.
Tilray Inc. (NASDAQ:TLRY) earlier this week announced it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function. “The Effects of Medicinal Cannabinoids on Driving” study was a double blind, placebo-controlled study that compared the effects of two varieties of cannabis – a variety containing high levels of THC and a variety containing a 1:1 balanced ratio of THC:CBD – to a placebo, which contained neither THC nor CBD. Tilray supplied the cannabis varieties for the study from its Good Manufacturing Practices (GMP) certified facility in Nanaimo, British Columbia. “We studied the extent to which cannabis affects driving and specifically, whether CBD moderates the effects of THC,” says Thomas Arkell, a Lambert Initiative researcher, who oversaw the trial. “The two main objectives of the six-month study were to characterise and understand how vaporized cannabis effects people’s driving and to establish whether there are differences in the effects of cannabis containing either high THC and very little CBD or a 1:1 balanced ratio of THC and CBD”.
Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) on Thursday announced that the company, through its wholly owned subsidiary Aurora Europe GmbH, has been selected by the Luxembourg Health Ministry for the supply of medical cannabis to that country and an initial purchase order for approximately 20 kilograms has been received. The Company has received all required authorizations (import and export licenses) and has commenced its first shipment of high-grade medical cannabis to Luxembourg’s Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from a European government. “To our knowledge, Aurora is the first medical cannabis producer selected by the Luxembourg Health Ministry to supply dried cannabis flower,” said Neil Belot, Chief Global Business Development Officer.
MedMen Enterprises Inc. (CSE:MMEN.CN) (OTCQX:MMNFF) recently announced it has closed the acquisition process of Omaha Management Services, LLC’s Monarch Dispensary. Omaha Management Services, a subsidiary of WhiteStar Solutions LLC, operated the Monarch Dispensary which happened to be the first cannabis dispensary of its kind in Scottsdale, Arizona. According to the terms of the agreement, MedMen will assume possession of Whitestar’s co-manufacturing and licensing agreement with “Kiva, Mirth Provisions and HUXTON for the state of Arizona.” The Monarch Dispensary which held a cannabis license issued by the state of Arizona and operated a cannabis cultivation and processing facility will be instrumental in introducing MedMen into the lucrative cannabis market. The acquisition deal was settled in 80% equity and 20% cash.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST Aggressive Development of Newest CBD Based Medicinal Products Occupying Large Share of Cannabis Industry
Aggressive Development of Newest CBD Based Medicinal Products Occupying Large Share of Cannabis Industry
December 7, 2018
Palm Beach, FL – (December 7, 2018) – The medicinal market within the overarching and extremely active cannabis industry has long been dominated by medicinal products based in cannabidiol, or CBD. CBD medicines have leveraged a compound from cannabis that does not create a high, but it is believed to have a wide variety of health benefits, including fighting inflammation and other everyday ailments. Greenwave Advisors estimates the CBD market as a whole could reach $3 billion in the United States within three years. Industry specialists believe that CBD could outstrip the rest of the cannabis sector in size in the next few years as a wide variety of end-use product potential is helping CBD based products gain mainstream use and global acceptance. Active cannabis companies in the markets this week include Earth Science Tech, Inc. (OTC:ETST), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED), Tilray Inc. (NASDAQ:TLRY), Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB), MedMen Enterprises Inc. (CSE:MMEN) (OTC:MMNFF).
Earth Science Tech, Inc. (OTCQB: ETST) BREAKING NEWS: Earth Science Tech, an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that the new genuine CBD/Propovit throat spray formula developed through a strategic partnership with Bionatus is nearly market-ready.
As previously announced, ETST collaborated with Bionatus to improve the Propovit throat spray. The result is a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp.
Dr. Michel Aube, ETST’s CEO and chief science officer states, “We are very excited to see this project in the final stage. We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation. ”
The main active ingredient in Propovit is propolis, a compound derived from the Brazilian green bee and packed with strong antioxidants as well as potent anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties. The new formulation combines the effect of Propovit and ETST’s cannabinoids to help diminish the symptoms of throat infections via fine drops that spread the hemp oil widely onto the oromucosal part of the mouth.
ETST also plans to conduct clinical trials on the genuine CBD/Propovit formula to measure the combined effects of these two powerful components on throat infections. Read this and more news for ETST at https://www.financialnewsmedia.com/news-etst
Other recent developments in the cannabis industry include:
Canopy Growth Corporation (NYSE:CGC) (TSX:WEED) on Thursday announced it has finalized an all-cash transaction to acquire Storz & Bickel GmbH & Co. KG, related entities, and IP (collectively, “Storz & Bickel” or “S&B”) for a purchase price of up to approximately €145 million. With a 22-year track record of breakthrough innovations, Storz & Bickel is widely recognized as the global leader in vaporizer design and manufacturing. Based in Tuttlingen, Germany, Storz & Bickel are designers and manufacturers of medically approved vaporizers, most notably the Volcano® Medic and the Mighty® Medic. Storz & Bickel has spent the last two decades developing an automated and internationally certified factory, achieving ISO 13485 certification in 2009. The company has exported devices to 50 markets around the world.
Tilray Inc. (NASDAQ:TLRY) earlier this week announced it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function. “The Effects of Medicinal Cannabinoids on Driving” study was a double blind, placebo-controlled study that compared the effects of two varieties of cannabis – a variety containing high levels of THC and a variety containing a 1:1 balanced ratio of THC:CBD – to a placebo, which contained neither THC nor CBD. Tilray supplied the cannabis varieties for the study from its Good Manufacturing Practices (GMP) certified facility in Nanaimo, British Columbia. “We studied the extent to which cannabis affects driving and specifically, whether CBD moderates the effects of THC,” says Thomas Arkell, a Lambert Initiative researcher, who oversaw the trial. “The two main objectives of the six-month study were to characterise and understand how vaporized cannabis effects people’s driving and to establish whether there are differences in the effects of cannabis containing either high THC and very little CBD or a 1:1 balanced ratio of THC and CBD”.
Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) on Thursday announced that the company, through its wholly owned subsidiary Aurora Europe GmbH, has been selected by the Luxembourg Health Ministry for the supply of medical cannabis to that country and an initial purchase order for approximately 20 kilograms has been received. The Company has received all required authorizations (import and export licenses) and has commenced its first shipment of high-grade medical cannabis to Luxembourg’s Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from a European government. “To our knowledge, Aurora is the first medical cannabis producer selected by the Luxembourg Health Ministry to supply dried cannabis flower,” said Neil Belot, Chief Global Business Development Officer.
MedMen Enterprises Inc. (CSE:MMEN.CN) (OTCQX:MMNFF) recently announced it has closed the acquisition process of Omaha Management Services, LLC’s Monarch Dispensary. Omaha Management Services, a subsidiary of WhiteStar Solutions LLC, operated the Monarch Dispensary which happened to be the first cannabis dispensary of its kind in Scottsdale, Arizona. According to the terms of the agreement, MedMen will assume possession of Whitestar’s co-manufacturing and licensing agreement with “Kiva, Mirth Provisions and HUXTON for the state of Arizona.” The Monarch Dispensary which held a cannabis license issued by the state of Arizona and operated a cannabis cultivation and processing facility will be instrumental in introducing MedMen into the lucrative cannabis market. The acquisition deal was settled in 80% equity and 20% cash.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Earth Science Tech, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $ETST Earth Science Tech, Inc. (ETST) Announces Final Formulation of CBD/Propovit Throat Spray Product
Earth Science Tech, Inc. (ETST) Announces Final Formulation of CBD/Propovit Throat Spray Product
DORAL, Florida, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that the new genuine CBD/Propovit throat spray formula developed through a strategic partnership with Bionatus is nearly market-ready.
As previously announced, ETST collaborated with Bionatus to improve the Propovit throat spray. The result is a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp.
Dr. Michel Aube, ETST’s CEO and chief science officer states, “We are very excited to see this project in the final stage. We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation. ”
The main active ingredient in Propovit is propolis, a compound derived from the Brazilian green bee and packed with strong antioxidants as well as potent anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties. The new formulation combines the effect of Propovit and ETST’s cannabinoids to help diminish the symptoms of throat infections via fine drops that spread the hemp oil widely onto the oromucosal part of the mouth.
ETST also plans to conduct clinical trials on the genuine CBD/Propovit formula to measure the combined effects of these two powerful components on throat infections.
“The focus and patience of this project are rewarding. The determination of our team to continuously propel ETST is what fuels our success. We are united in our goal to deliver to people the best products to help them to have a better and healthier life,” states ETST president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Announces Final Formulation of CBD/Propovit Throat Spray Product
Earth Science Tech, Inc. (ETST) Announces Final Formulation of CBD/Propovit Throat Spray Product
DORAL, Florida, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces that the new genuine CBD/Propovit throat spray formula developed through a strategic partnership with Bionatus is nearly market-ready.
As previously announced, ETST collaborated with Bionatus to improve the Propovit throat spray. The result is a new strawberry-flavored formulation enriched with ETST full-spectrum cannabinoids derived from industrial hemp.
Dr. Michel Aube, ETST’s CEO and chief science officer states, “We are very excited to see this project in the final stage. We have developed a product that we believe will have properties not found in any other product on the market, and we thank our team and our partner Bionatus for their diligence and innovation on this formulation. ”
The main active ingredient in Propovit is propolis, a compound derived from the Brazilian green bee and packed with strong antioxidants as well as potent anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties. The new formulation combines the effect of Propovit and ETST’s cannabinoids to help diminish the symptoms of throat infections via fine drops that spread the hemp oil widely onto the oromucosal part of the mouth.
ETST also plans to conduct clinical trials on the genuine CBD/Propovit formula to measure the combined effects of these two powerful components on throat infections.
“The focus and patience of this project are rewarding. The determination of our team to continuously propel ETST is what fuels our success. We are united in our goal to deliver to people the best products to help them to have a better and healthier life,” states ETST president, director and Chairman Nickolas S. Tabraue.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $PYTG Active Uses and Applications for CBD Based Medicinal Products Feeding into Growing Billion Dollar Market
Active Uses and Applications for CBD Based Medicinal Products Feeding into Growing Billion Dollar Market
December 6, 2018
Palm Beach, FL – (December 6, 2018) – According to an article published on RollingStone.com, for years experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it turns out that one market is spinning off into a mega-industry of its own: according to a new estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022. And of the CBD industry, the pet-care industry is thought to be one of the fastest growing markets as consumers show an increased desire to spend more on their furry friends, even if it means paying a premium. According to the American Pet Products Association, Americans spent nearly $70 billion on their pets in 2017, marking an all-time high water mark for the industry. One of the largest facets of the market is health care, and this is where leaders in the CBD industry are aiming to capitalize on. Alternative medicines and treatments have been quickly gaining popularity among consumers. This has also been true when it comes to pet owners and how they treat their animals, with holistic and natural remedies quickly rising in demand. Leaders in the CBD industry are leveraging product development and research to translate this demand into new and lucrative revenue streams. Active Companies from around the market with current developments this week include: Pyramidion Technology Group, Inc. (OTC:PYTG), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED), Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Pyxus International Inc. (NYSE:PYX).
Pyramidion Technology Group, Inc. (OTCPK:PYTG) BREAKING NEWS: Pyramidion Technology Group’s, LeafyWell (www.LeafyWell.com) that produces a broad selection of Cannabidiol (“CBD”) containing products such as tinctures, oils, creams and lotions, and edible gummy candies has announced today that they will expand its product lines to include specifically formulated sprays and treats designed for pets to address anxiety, nervousness, arthritis and inflammation, and ailments in digestion, among others.
Research investigating the effects of CBD have produced positive findings thereby supporting its use in the treatment of a variety of conditions and ailments such as rheumatoid arthritis, diabetes, post-traumatic stress disorder, epilepsy, antibiotic-resistant infections, neurological disorders, and muscular dystrophy in humans. LeafyWell www.LeafyWell.com is now branching out with pet specific formulations designed for a variety of health concerns in animals with delivery methods intended to be suitable for domesticated pets including both treats and sprays. Currently, dog and cat treats are offered in the following flavors: Bacon, Steak, Jerky, Pigs in a Blanket, Bones and Meatballs. The current collection line of pet designed sprays have no added flavor and are designed to be added to either food or water, or given orally directly to pets.
According to some reported statistics, the pet treat industry is a billion-dollar industry placing pet treat sales upwards of $5 billion dollars in the US alone in 2018 while pet food sales exceed $25 billion dollars. Moreover, it has also been reported that around 24% of owners seek out treats designed to address specific health issues. The LeafyWell www.LeafyWell.com pet collection is currently available via e-commerce and perhaps in the future we will see the entire product line on display shelves in retail brick and mortar pet stores and directly purchasable online via pet store websites.
“We are excited to announce our newest product line offerings to include formulations and delivery methods designed specifically for dogs and cats. Our intention is to offer a staple in home pet products for consumers available for purchase in a variety of methods and in a variety of flavors and delivery methods. The pet industry appears to be ready for our products and we anticipate great things to come for our clients and our investors from our pet product line launch. We also feel that the timing of our launch is right on schedule with our company’s goals as well as making our products available just in time for the holidays.”, states Carlos Hurtado, CEO of PYTG. Read this and more news for PYTG at http://www.financialnewsmedia.com/news-pytg
In the industry developments and happenings in the market this week include:
Canopy Growth Corporation (NYSE:CGC) (TSX:WEED) earlier this week announced it has entered into two agreements with 48North Cannabis Corp. (“48North”) (NRTH.V) a strategic investment financing (“Financing Agreement”) and partnership and a supply agreement (“Supply Agreement”). Under the Supply Agreement, 48North will supply Canopy Growth with dried cannabis produced from high-grade, unique genetics, grown at 48North’s wholly-owned facility, DelShen Therapeutics Corp. (“DelShen”). The total volume of the Supply Agreement is estimated to be a minimum of 1,200 kilograms and deliverable over the course of 12 months. The first 100-kilogram transfer under the Supply Agreement is expected to ship from 48North’s DelShen facility to Canopy Growth by December 5, 2018. Under the Financing Agreement, Canopy will invest $3 million into 48North and receive 4,000,000 Common Units (“Units”) at $0.75 per Unit. 48North will issue each Unit at $0.75 to Canopy Growth for $3 million, representing approximately 3.4% of the issued and outstanding shares. Each Unit will be comprised of one Common Share and one quarter Common Share Purchase Warrant (each whole Common Share Purchase Warrant, a “Warrant”). Each full Warrant will entitle the holder to acquire an additional Common Share of 48North for a period of 12 months from the date of issue at a strike price of $1.15 , provided that, the expiry of the warrants can be accelerated if the closing price of 48North’s common shares on the TSX Venture Exchange (“TSXV”) is at least $1.50 for a minimum of 10 consecutive trading days and a notice of acceleration is provided, in accordance with the terms of the warrant, to a date 30 days after the date of the notice.
Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) earlier this week announced that, further to its October 17, 2018 announcement that it had received a sales license from Health Canada permitting the sale of cannabis softgel capsules, the Company has commenced shipments for both the Canadian medical and adult-use markets. Aurora expects to commence exports to international markets in early 2019. At scale, the Company anticipates that softgel production at its state-of-the-art Aurora Vie facility in Quebec will reach at least 1.4 million capsules per week. Aurora intends to make this high-volume, high-margin, smoke-free, product available to all of its domestic and international target markets over time where legally possible. Aurora’s softgel capsules are produced to pharmaceutical-grade standards at Aurora Vie, in collaboration with leading softgel manufacturer Capcium Inc. (“Capcium”), in which Aurora holds a 19.99% ownership interest. The Company will initially launch the capsules to the medical cannabis market in Canada as well as the adult-use market in British Columbia with additional provincial markets to follow.
Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) recently confirmed that it is engaged in discussions concerning a potential investment by Altria Group Inc. (MO) (“Altria Group”) in Cronos Group. No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies. Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across five continents. Cronos Group operates two wholly-owned Canadian licensed producers: Peace Naturals Project Inc., which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd., which is based in the Okanagan Valley, British Columbia. Cronos Group has multiple international production and distribution platforms across five continents. Cronos Group intends to continue to rapidly expand its global footprint as it focuses on building an international iconic brand portfolio and developing disruptive intellectual property. Cronos Group is committed to building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience.
Pyxus International Inc. (NYSE:PYX) recently announced that its joint venture, Criticality, an integrated North Carolina-based industrial hemp company operating under North Carolina’s industrial hemp pilot program, has launched “Korent,” its new line of cannabidiol (CBD) oil products. Korent’s full-spectrum oil drops are available in Vanilla Mint and Grape flavors, in multiple sizes and concentrations. Flavors were custom designed for hemp products in partnership with Purilum, LLC, a leading flavor manufacturer and Pyxus-affiliated company. “Criticality’s science-based approach to the extraction, refinement and formulation of high-quality CBD products makes it well positioned in the market and presents a huge growth opportunity for both Criticality and Pyxus,” said Pieter Sikkel, Pyxus’ president, CEO and chairman of the board.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty nine hundred dollars for news coverage of the current press release issued by Pyramidion Technology Group, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $POTN Diamond CBD Goes Funny In New CBD Educational Awareness Ad Campaign
Diamond CBD Goes Funny In New CBD Educational Awareness Ad Campaign
"I am THC, I am CBD" video shorts use humor and nostalgia to dispel myths about hemp-derived CBD
MIAMI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), and leader in hemp extraction and innovative CBD products for the wellness market, kicked off their nationwide educational campaign with a series of video shorts aimed at introducing CBD to a mainstream market. Called, "I am THC, I am CBD," the videos deftly mix humor and nostalgia to reach their ultimate goal of dispelling the myths about CBD commonly held by general audiences who are unfamiliar with the extract.
The brainchild of the Miami-based marketing solutions team at Creative Propulsion Labs, "I am THC, I am CBD" takes inspiration from the classic "Get a Mac" ad campaign developed for Apple Inc. in the late 2000s. In a nostalgic nod to those ads, the "I am THC, I am CBD" campaign sees two actors appropriate the personas of THC and CBD, respectively, with brief but humorous exchanges that ultimately find CBD prevailing over THC in some way.
"Although the market is expected to grow to almost $2 billion in the next decade, a good number of people still carry misconceptions about what CBD is and isn't," said Kevin Hagen, the CEO of PotNetwork Holdings, which owns Diamond CBD. "We wanted a way to introduce CBD to everyone; your mom, your uncle, your best friend without seeming too off-putting or too technical. When Adam Mizrahi [CEO of Creative Propulsion Labs] and the team came to us with this idea, we knew it would be a hit from the start."
The campaign is part of a broader push by Diamond CBD to both bring CBD to the mainstream and to raise the standards of the industry as a whole. Recently, Hagen put out a call to arms of sorts, challenging the industry to become more accountable to consumers through tougher quality checkpoints. It's a movement that Diamond CBD believes they can spearhead, through leading by example.
Along with the video campaign, the company will launch a CBD Education Center called, "What is CBD," which will become the official repository on the web for factual, up-to-date information about CBD. Diamond CBD has also added to its already high-quality standards, with increased product testing and increased transparency for consumers as well.
"Diamond CBD has always held to the highest standards possible within the CBD industry, placing consumers first," said Hagen. "Now, we challenge the rest of the industry to join us."
The "I am THC, I am CBD" campaign will be available on the web at DiamondCBD.com, as well as on other high traffic channels frequented by target demographics.
About Diamond CBD, Inc.: Diamond CBD focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD's team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, and vape liquids found anywhere. For more information, please visit its website at www.DiamondCBD.com.
About PotNetwork Holdings, Inc.: PotNetwork Holdings, Inc. (OTC Pink: POTN) is a publicly traded company that acts as a holding company for its principal subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD products. For more information, please visit its website at www.PotNetworkholding.com
Safe Harbor: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:PotNetwork Holdings, Inc.
Investor Relations: Marisol Elwell
1-800-915-3060 investor@PotNetworkHolding.com
LOGO.jpg
News: $PYTG LeafyWell.com, a Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Announces CBD Pet Product Launch
LeafyWell.com, a Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Announces CBD Pet Product Launch
WESTON, Florida, December 6, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc. (OTCPK: PYTG), LeafyWell (http://www.LeafyWell.com) produces a broad selection of Cannabidiol ("CBD") containing products such as tinctures, oils, creams and lotions, and edible gummy candies has announced today that they will expand its product lines to include specifically formulated sprays and treats designed for pets to address anxiety, nervousness, arthritis and inflammation, and ailments in digestion, among others.
Research investigating the effects of CBD have produced positive findings thereby supporting its use in the treatment of a variety of conditions and ailments such as rheumatoid arthritis, diabetes, post-traumatic stress disorder, epilepsy, antibiotic-resistant infections, neurological disorders, and muscular dystrophy in humans. LeafyWell http://www.LeafyWell.com is now branching out with pet specific formulations designed for a variety of health concerns in animals with delivery methods intended to be suitable for domesticated pets including both treats and sprays. Currently, dog and cat treats are offered in the following flavors: Bacon, Steak, Jerky, Pigs in a Blanket, Bones and Meatballs. The current collection line of pet designed sprays have no added flavor and are designed to be added to either food or water, or given orally directly to pets.
According to some reported statistics, the pet treat industry is a billion-dollar industry placing pet treat sales upwards of $5 billion dollars in the US alone in 2018 while pet food sales exceed $25 billion dollars. Moreover, it has also been reported that around 24% of owners seek out treats designed to address specific health issues. The LeafyWell http://www.LeafyWell.com pet collection is currently available via e-commerce and perhaps in the future we will see the entire product line on display shelves in retail brick and mortar pet stores and directly purchasable online via pet store websites.
Our collection of CBD LeafyWell Pet products can be found at the following web addresses:
1. CBD Pet Treats Meatballs 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-meatballs
2. CBD Pet Treats Jerky 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-jerky
3. CBD Pet Treats Steak 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-steak
4. CBD Pet Treats Bones 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-bones
5. CBD Pet Treats Pigs In A Blanket 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-pigs-in-a-blanket
6. CBD Pet Treats Bacon 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-bacon
7.CBD Pet Spray 100mg Dogs/Cats - https://www.leafywell.com/collections/pet-products/products/cbd-pet-spray-100mg-dogs-cats
"We are excited to announce our newest product line offerings to include formulations and delivery methods designed specifically for dogs and cats. Our intention is to offer a staple in home pet products for consumers available for purchase in a variety of methods and in a variety of flavors and delivery methods. The pet industry appears to be ready for our products and we anticipate great things to come for our clients and our investors from our pet product line launch. We also feel that the timing of our launch is right on schedule with our company's goals as well as making our products available just in time for the holidays," states Carlos Hurtado, CEO of PYTG.
The entire CBD pet product line can be found at https://www.LeafyWell.com/collections/pet-products with both individual purchase options as well as bundled purchase options including both treats and sprays.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide
variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
News: $PYTG LeafyWell.com, a Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Announces CBD Pet Product Launch
LeafyWell.com, a Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Announces CBD Pet Product Launch
WESTON, Florida, December 6, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc. (OTCPK: PYTG), LeafyWell (http://www.LeafyWell.com) produces a broad selection of Cannabidiol ("CBD") containing products such as tinctures, oils, creams and lotions, and edible gummy candies has announced today that they will expand its product lines to include specifically formulated sprays and treats designed for pets to address anxiety, nervousness, arthritis and inflammation, and ailments in digestion, among others.
Research investigating the effects of CBD have produced positive findings thereby supporting its use in the treatment of a variety of conditions and ailments such as rheumatoid arthritis, diabetes, post-traumatic stress disorder, epilepsy, antibiotic-resistant infections, neurological disorders, and muscular dystrophy in humans. LeafyWell http://www.LeafyWell.com is now branching out with pet specific formulations designed for a variety of health concerns in animals with delivery methods intended to be suitable for domesticated pets including both treats and sprays. Currently, dog and cat treats are offered in the following flavors: Bacon, Steak, Jerky, Pigs in a Blanket, Bones and Meatballs. The current collection line of pet designed sprays have no added flavor and are designed to be added to either food or water, or given orally directly to pets.
According to some reported statistics, the pet treat industry is a billion-dollar industry placing pet treat sales upwards of $5 billion dollars in the US alone in 2018 while pet food sales exceed $25 billion dollars. Moreover, it has also been reported that around 24% of owners seek out treats designed to address specific health issues. The LeafyWell http://www.LeafyWell.com pet collection is currently available via e-commerce and perhaps in the future we will see the entire product line on display shelves in retail brick and mortar pet stores and directly purchasable online via pet store websites.
Our collection of CBD LeafyWell Pet products can be found at the following web addresses:
1. CBD Pet Treats Meatballs 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-meatballs
2. CBD Pet Treats Jerky 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-jerky
3. CBD Pet Treats Steak 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-steak
4. CBD Pet Treats Bones 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-bones
5. CBD Pet Treats Pigs In A Blanket 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-pigs-in-a-blanket
6. CBD Pet Treats Bacon 100mg - https://www.leafywell.com/collections/pet-products/products/cbd-pet-treats-bacon
7.CBD Pet Spray 100mg Dogs/Cats - https://www.leafywell.com/collections/pet-products/products/cbd-pet-spray-100mg-dogs-cats
"We are excited to announce our newest product line offerings to include formulations and delivery methods designed specifically for dogs and cats. Our intention is to offer a staple in home pet products for consumers available for purchase in a variety of methods and in a variety of flavors and delivery methods. The pet industry appears to be ready for our products and we anticipate great things to come for our clients and our investors from our pet product line launch. We also feel that the timing of our launch is right on schedule with our company's goals as well as making our products available just in time for the holidays," states Carlos Hurtado, CEO of PYTG.
The entire CBD pet product line can be found at https://www.LeafyWell.com/collections/pet-products with both individual purchase options as well as bundled purchase options including both treats and sprays.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide
variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Announces Deep Discounts for Cyber Monday
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Announces Deep Discounts for Cyber Monday
Innovative biotechnology company Earth Science Tech, Inc. (OTCQB: ETST) today announced its deepest discounts for online orders. The Cyber Monday discount is available from now until midnight, with 50 percent off of all online orders using promo code CYBERMONDAY at checkout. In addition, ETST is offering its deepest wholesale account discounts through the end of November. Those interested in wholesale account pricing and deals should email Sales@EarthScienceTech.com or call the company directly at (305) 615-2118.
To view the full press release, visit: http://nnw.fm/4Lemc
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsBreaks
NetworkNewsBreaks – Global Payout, Inc. (GOHE) Expanding to Three New States with Signing of Two of the Largest US Cannabis Companies
NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) to be a Presenting Company at 11th Annual LD Micro Main Event
NetworkNewsBreaks – SinglePoint, Inc. (SING) Management Discusses Cannabis Sector Growth and Opportunities at MJBizCon’s Podcast Row
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST NetworkNewsBreaks - Earth Science Tech, Inc. (ETST) Announces Deep Discounts for Cyber Monday
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Announces Deep Discounts for Cyber Monday
Innovative biotechnology company Earth Science Tech, Inc. (OTCQB: ETST) today announced its deepest discounts for online orders. The Cyber Monday discount is available from now until midnight, with 50 percent off of all online orders using promo code CYBERMONDAY at checkout. In addition, ETST is offering its deepest wholesale account discounts through the end of November. Those interested in wholesale account pricing and deals should email Sales@EarthScienceTech.com or call the company directly at (305) 615-2118.
To view the full press release, visit: http://nnw.fm/4Lemc
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsBreaks
NetworkNewsBreaks – Global Payout, Inc. (GOHE) Expanding to Three New States with Signing of Two of the Largest US Cannabis Companies
NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) to be a Presenting Company at 11th Annual LD Micro Main Event
NetworkNewsBreaks – SinglePoint, Inc. (SING) Management Discusses Cannabis Sector Growth and Opportunities at MJBizCon’s Podcast Row
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
News: $ETST Earth Science Tech, Inc. (ETST) Announces Cyber Monday 50% Discount and Steepest Wholesale Account Deals
Earth Science Tech, Inc. (ETST) Announces Cyber Monday 50% Discount and Steepest Wholesale Account Deals
DORAL, Florida, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces its deepest discount for all online orders, as well as the biggest wholesale account discount.
To view the Company’s broad range of cannabinoid products, visit https://EarthScienceTech.com. From now until midnight, all online orders are 50% off using promo code CYBERMONDAY at checkout.
Alongside the Cyber Monday online discount, Earth Science Tech is offering its deepest wholesale account discounts through the end of November. For wholesale account pricing and deals, email Sales@EarthScienceTech.com or call the company directly at (305) 615-2118.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: https://EarthScienceTech.com/
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com.
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com.
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com.
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
www.EarthScienceTech.com
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $ETST Earth Science Tech, Inc. (ETST) Announces Cyber Monday 50% Discount and Steepest Wholesale Account Deals
Earth Science Tech, Inc. (ETST) Announces Cyber Monday 50% Discount and Steepest Wholesale Account Deals
DORAL, Florida, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces its deepest discount for all online orders, as well as the biggest wholesale account discount.
To view the Company’s broad range of cannabinoid products, visit https://EarthScienceTech.com. From now until midnight, all online orders are 50% off using promo code CYBERMONDAY at checkout.
Alongside the Cyber Monday online discount, Earth Science Tech is offering its deepest wholesale account discounts through the end of November. For wholesale account pricing and deals, email Sales@EarthScienceTech.com or call the company directly at (305) 615-2118.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: https://EarthScienceTech.com/
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com.
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com.
KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com.
Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Nickolas S. Tabraue
President, Director & Chairman
www.EarthScienceTech.com
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
logo.jpg
News: $PYTG Cannabis Revolution Picking Up Steam with Introduction of Newest Products and Joint Ventures
Cannabis Revolution Picking Up Steam with Introduction of Newest Products and Joint Ventures
November 20, 2018
Palm Beach, FL – (November 20, 2018) – As the cannabis industry continues to skyrocket behind recent legalization in Canada as well as enhanced legalization momentum in the United States, the number of the latest and greatest cannabis-based products continue to rise and gaining momentum. Companies are producing unique and innovative products to maximize profit margins with rising revenues as well acquiring or jumping into joint ventures. Cannabis trade shows are becoming a regularity, attracting thousands upon thousands of attendees as industry leaders exhibit their products and market to the masses, aiming to grab a piece of the billion dollar space. One step into the recent annual Marijuana Business Conference just held in Las Vegas and one was able to witness the massive growth of the industry. Active Companies from around the market with current developments this week include: Pyramidion Technology Group, Inc. (OTC:PYTG), MariMed Inc. (OTC:MRMD), Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED), Charlotte’s Web Holdings Inc. (CSE:CWEB) (OTC:CWBHF).
Pyramidion Technology Group, Inc. (OTCPK:PYTG) BREAKING NEWS: Pyramidion Technology Group 100% owner of NxGen Brands (“NxGen”) d/b/a: LeafyWell.com (“www.LeafyWell.com”) specializing in CBD products, today announced the execution of a binding letter of intent to acquire Renaissance Health Publishing, LLC. (“Renaissance or the “Company”) – a Florida-based company specializing in health and wellness supplements.
Under this agreement, NxGen will acquire 100% of the assets of Renaissance Health Publishing, LLC in cash and stock to complete the acquisition. NxGen will also receive a robust customer base, existing staff and outstanding management team, as well as unique marketing materials and methods designed to advertise the current and existing Renaissance Health Publishing, LLC product lines.
Renaissance is a nationally-known research and development company recognized for its physician-developed, natural health supplements designed to provide health and wellness benefits such as anti-aging, testosterone-boosting, memory-supporting, and libido-boosting effects. Renaissance is perhaps best known for formulating and distributing their own exclusive physician-designed health and wellness supplements manufactured with top-quality ingredients. As a socially-responsible company, they do not perform any animal testing of any kind or at any point during their product research and development. Details on the complete Renaissance product line can be found at RenownHealthProducts.com.
CEO of PYTG, Carlos Hurtado, commented “We feel that the product lines of Renaissance Health Publishing are of the best on the market and we attribute their incredible success to the quality of the products themselves which have contributed to their long-standing reputation. They have established a numerous customer base and we feel that with this acquisition, and the synergy that these products may have with our products at www.LeafyWell.com, both our customers and our shareholders will be pleased. It just makes sense – both LeafyWell and Renaissance focus on health and wellness and it is a unique opportunity for us to acquire this company and have the opportunity to increase our customer base – current LeafyWell customers may enjoy the nutraceuticals currently formulated by Renaissance, current Renaissance customers may enjoy the www.LeafyWell.com product line, and new customers may enjoy either or both product lines. In our opinion, it is an all-around step in the right direction and we look forward to the effect that this new acquisition would have on our company.” Read this and more news for PYTG at http://www.financialnewsmedia.com/news-pytg
In the industry developments and happenings in the market this week include:
MariMed Inc. (OTCQB:MRMD) and GenCanna Global Inc. recently announced that the companies have entered into an agreement whereby MariMed has invested $30 million in GenCanna, and the companies have created a strategic partnership, including a long-term supply agreement. The partnership expands MariMed’s robust product development capabilities and strengthens GenCanna’s position as a global leader in the Hemp CBD industry. MariMed, a multi-state operator that develops and manages cannabis facilities and branded product lines, intends to create a product and branding business unit focused on the development and distribution of Hemp CBD-derived products. GenCanna is deploying the proceeds of the investment to dramatically expand its production capacity, and extend its position as the global leader in high-quality hemp CBD production, with fully legal sales throughout the U.S. and internationally. In recent years, GenCanna has assembled top-quality genetics for cultivating hemp, and has established production processes that meet or exceed Good Manufacturing Practices (GMP) standards, as well as the highest FDA standards.
Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT.TO) recently announced its financial and operating results for the 3-month period ended September 30, 2018. All amounts are in Canadian dollars.”We are progressing through the cannabis licensing process with Health Canada, having submitted our Evidence Package. We are at the final stages of this process, and our Sherbrooke facility will begin operations shortly following the receipt of our Producers Licence pursuant to Cannabis Regulation (CR),” stated Jim Hamilton, President and Chief Executive Officer. “Our Phase II capacity expansion is moving ahead on time and is expected to be completed by March 2019, significantly raising our production capability to 200,000 kg of dried cannabis using advanced extraction techniques.” “In the nutraceutical business, we continued to deliver revenue growth during the second quarter, while advancing toward our goal of commercializing our B2B cannabis extraction operations. We remain in a solid financial position with over $20 million in cash and, with supply agreements booked and projected opportunities, our plan remains for our cannabis operations to achieve positive EBITDA within our first year of production,” concluded Mr. Hamilton.
Canopy Growth Corporation (NYSE:CGC) (TSX:WEED.TO) recently announced it has entered into a multi-year agreement with The Brink’s Company (BCO) through its Brink’s Canada subsidiary to provide secure logistics and cash management services for Canopy Growth’s domestic and international cannabis operations. The Brink’s Company is the global leader in total cash management, secure route-based logistics and payment solutions and its global infrastructure will allow Canopy Growth to scale efficiently as its logistics needs become increasingly complex. “Brinks’ reputation as a trusted industry leader has been earned by providing reliable secure transport services for over 90 years in Canada ,” said Mark Zekulin , President and Co-CEO, Canopy Growth. “As a cannabis producer with growing national and international needs, we are proud to enter into this agreement and look forward to working with Brink’s to consistently deliver a variety of high-quality cannabis products to our retail locations and affiliates across the country.”
Charlotte’s Web Holdings Inc. (CSE:CWEB.CN) (OTCQX:CWBHF) recently announced it has surpassed 3000 retail locations across the United States. At the end of 2017, Charlotte’s Web products were sold in approximately 2,000 locations. The Company disclosed today that it surpassed its 2018 year-end goal of 3,000 locations during the 3rd quarter. “Firstly, I would like to commend our incredible and committed staff who worked tirelessly to achieve this milestone,” stated Charlotte’s Web CEO Hess Moallem. “I would also like to thank our dedicated retail partners for their continued support of our mission and for valuing the trust that is closely associated with our brand name.” With CBD gaining mainstream market momentum, Charlotte’s Web, the industry pioneer and category leader in hemp-based CBD, has expanded its suite of product offerings across a wider variety of retailers, from small specialty health food stores to now including regional pharmacy and grocery chains. The Company recently added more than 40 Bartell drug stores in the North West.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty five hundred dollars for news coverage of the current press release issued by Pyramidion Technology Group, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $PYTG Cannabis Revolution Picking Up Steam with Introduction of Newest Products and Joint Ventures
Cannabis Revolution Picking Up Steam with Introduction of Newest Products and Joint Ventures
November 20, 2018
Palm Beach, FL – (November 20, 2018) – As the cannabis industry continues to skyrocket behind recent legalization in Canada as well as enhanced legalization momentum in the United States, the number of the latest and greatest cannabis-based products continue to rise and gaining momentum. Companies are producing unique and innovative products to maximize profit margins with rising revenues as well acquiring or jumping into joint ventures. Cannabis trade shows are becoming a regularity, attracting thousands upon thousands of attendees as industry leaders exhibit their products and market to the masses, aiming to grab a piece of the billion dollar space. One step into the recent annual Marijuana Business Conference just held in Las Vegas and one was able to witness the massive growth of the industry. Active Companies from around the market with current developments this week include: Pyramidion Technology Group, Inc. (OTC:PYTG), MariMed Inc. (OTC:MRMD), Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED), Charlotte’s Web Holdings Inc. (CSE:CWEB) (OTC:CWBHF).
Pyramidion Technology Group, Inc. (OTCPK:PYTG) BREAKING NEWS: Pyramidion Technology Group 100% owner of NxGen Brands (“NxGen”) d/b/a: LeafyWell.com (“www.LeafyWell.com”) specializing in CBD products, today announced the execution of a binding letter of intent to acquire Renaissance Health Publishing, LLC. (“Renaissance or the “Company”) – a Florida-based company specializing in health and wellness supplements.
Under this agreement, NxGen will acquire 100% of the assets of Renaissance Health Publishing, LLC in cash and stock to complete the acquisition. NxGen will also receive a robust customer base, existing staff and outstanding management team, as well as unique marketing materials and methods designed to advertise the current and existing Renaissance Health Publishing, LLC product lines.
Renaissance is a nationally-known research and development company recognized for its physician-developed, natural health supplements designed to provide health and wellness benefits such as anti-aging, testosterone-boosting, memory-supporting, and libido-boosting effects. Renaissance is perhaps best known for formulating and distributing their own exclusive physician-designed health and wellness supplements manufactured with top-quality ingredients. As a socially-responsible company, they do not perform any animal testing of any kind or at any point during their product research and development. Details on the complete Renaissance product line can be found at RenownHealthProducts.com.
CEO of PYTG, Carlos Hurtado, commented “We feel that the product lines of Renaissance Health Publishing are of the best on the market and we attribute their incredible success to the quality of the products themselves which have contributed to their long-standing reputation. They have established a numerous customer base and we feel that with this acquisition, and the synergy that these products may have with our products at www.LeafyWell.com, both our customers and our shareholders will be pleased. It just makes sense – both LeafyWell and Renaissance focus on health and wellness and it is a unique opportunity for us to acquire this company and have the opportunity to increase our customer base – current LeafyWell customers may enjoy the nutraceuticals currently formulated by Renaissance, current Renaissance customers may enjoy the www.LeafyWell.com product line, and new customers may enjoy either or both product lines. In our opinion, it is an all-around step in the right direction and we look forward to the effect that this new acquisition would have on our company.” Read this and more news for PYTG at http://www.financialnewsmedia.com/news-pytg
In the industry developments and happenings in the market this week include:
MariMed Inc. (OTCQB:MRMD) and GenCanna Global Inc. recently announced that the companies have entered into an agreement whereby MariMed has invested $30 million in GenCanna, and the companies have created a strategic partnership, including a long-term supply agreement. The partnership expands MariMed’s robust product development capabilities and strengthens GenCanna’s position as a global leader in the Hemp CBD industry. MariMed, a multi-state operator that develops and manages cannabis facilities and branded product lines, intends to create a product and branding business unit focused on the development and distribution of Hemp CBD-derived products. GenCanna is deploying the proceeds of the investment to dramatically expand its production capacity, and extend its position as the global leader in high-quality hemp CBD production, with fully legal sales throughout the U.S. and internationally. In recent years, GenCanna has assembled top-quality genetics for cultivating hemp, and has established production processes that meet or exceed Good Manufacturing Practices (GMP) standards, as well as the highest FDA standards.
Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT.TO) recently announced its financial and operating results for the 3-month period ended September 30, 2018. All amounts are in Canadian dollars.”We are progressing through the cannabis licensing process with Health Canada, having submitted our Evidence Package. We are at the final stages of this process, and our Sherbrooke facility will begin operations shortly following the receipt of our Producers Licence pursuant to Cannabis Regulation (CR),” stated Jim Hamilton, President and Chief Executive Officer. “Our Phase II capacity expansion is moving ahead on time and is expected to be completed by March 2019, significantly raising our production capability to 200,000 kg of dried cannabis using advanced extraction techniques.” “In the nutraceutical business, we continued to deliver revenue growth during the second quarter, while advancing toward our goal of commercializing our B2B cannabis extraction operations. We remain in a solid financial position with over $20 million in cash and, with supply agreements booked and projected opportunities, our plan remains for our cannabis operations to achieve positive EBITDA within our first year of production,” concluded Mr. Hamilton.
Canopy Growth Corporation (NYSE:CGC) (TSX:WEED.TO) recently announced it has entered into a multi-year agreement with The Brink’s Company (BCO) through its Brink’s Canada subsidiary to provide secure logistics and cash management services for Canopy Growth’s domestic and international cannabis operations. The Brink’s Company is the global leader in total cash management, secure route-based logistics and payment solutions and its global infrastructure will allow Canopy Growth to scale efficiently as its logistics needs become increasingly complex. “Brinks’ reputation as a trusted industry leader has been earned by providing reliable secure transport services for over 90 years in Canada ,” said Mark Zekulin , President and Co-CEO, Canopy Growth. “As a cannabis producer with growing national and international needs, we are proud to enter into this agreement and look forward to working with Brink’s to consistently deliver a variety of high-quality cannabis products to our retail locations and affiliates across the country.”
Charlotte’s Web Holdings Inc. (CSE:CWEB.CN) (OTCQX:CWBHF) recently announced it has surpassed 3000 retail locations across the United States. At the end of 2017, Charlotte’s Web products were sold in approximately 2,000 locations. The Company disclosed today that it surpassed its 2018 year-end goal of 3,000 locations during the 3rd quarter. “Firstly, I would like to commend our incredible and committed staff who worked tirelessly to achieve this milestone,” stated Charlotte’s Web CEO Hess Moallem. “I would also like to thank our dedicated retail partners for their continued support of our mission and for valuing the trust that is closely associated with our brand name.” With CBD gaining mainstream market momentum, Charlotte’s Web, the industry pioneer and category leader in hemp-based CBD, has expanded its suite of product offerings across a wider variety of retailers, from small specialty health food stores to now including regional pharmacy and grocery chains. The Company recently added more than 40 Bartell drug stores in the North West.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty five hundred dollars for news coverage of the current press release issued by Pyramidion Technology Group, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
SOURCE Financialnewsmedia.com
News: $PYTG NxGen Brands Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Enters Into a Letter of Intent to Acquire Renaissance Health Publishing, LLC
NxGen Brands Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Enters Into a Letter of Intent to Acquire Renaissance Health Publishing, LLC
WESTON, Florida, November 20, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc (OTC: PYTG), 100% owner of NxGen Brands ("NxGen") d/b/a: LeafyWell.com ("http://www.LeafyWell.com") specializing in CBD products, today announced the execution of a binding letter of intent to acquire Renaissance Health Publishing, LLC. ("Renaissance or the "Company") - A Florida-based company specializing in health and wellness supplements.
Under this agreement, NxGen will acquire 100% of the assets of Renaissance Health Publishing, LLC in cash and stock to complete the acquisition. NxGen will also receive a robust customer base, existing staff and outstanding management team, as well as unique marketing materials and methods designed to advertise the current and existing Renaissance Health Publishing, LLC product lines.
Renaissance is a nationally-known research and development company recognized for its physician-developed, natural health supplements designed to provide health and wellness benefits such as anti-aging, testosterone-boosting, memory-supporting, and libido-boosting effects. Renaissance is perhaps best known for formulating and distributing their own exclusive physician-designed health and wellness supplements manufactured with top-quality ingredients. As a socially-responsible company, they do not perform any animal testing of any kind or at any point during their product research and development. Details on the complete Renaissance product line can be found at RenownHealthProducts.com.
CEO of PYTG, Carlos Hurtado, commented, "We feel that the product lines of Renaissance Health Publishing are of the best on the market and we attribute their incredible success to the quality of the products themselves which have contributed to their long-standing reputation. They have established a numerous customer base and we feel that with this acquisition and the synergy that these products may have with our products at http://www.LeafyWell.com, both our customers and our shareholders will be pleased. It just makes sense - both LeafyWell and Renaissance focus on health and wellness and it is a unique opportunity for us to acquire this company and have the opportunity to increase our customer base - current LeafyWell customers may enjoy the nutraceuticals currently formulated by Renaissance, current Renaissance customers may enjoy the http://www.LeafyWell.com product line, and new customers may enjoy either or both product lines. In our opinion, it is an all-around step in the right direction and we look forward to the effect that this new acquisition would have on our company."
The Letter of Intent from NxGen Brands to acquire Renaissance Health Publishing, LLC is a binding contract and the proposed acquisition is subject only to finalize the execution of a definitive purchase agreement. To that end, the proposed acquisition would be subject to due diligence and audit approvals.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
News: $PYTG NxGen Brands Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Enters Into a Letter of Intent to Acquire Renaissance Health Publishing, LLC
NxGen Brands Subsidiary of Pyramidion Technology Group, Inc. (OTC: PYTG) Enters Into a Letter of Intent to Acquire Renaissance Health Publishing, LLC
WESTON, Florida, November 20, 2018 /PRNewswire/ --
Pyramidion Technology Group, Inc (OTC: PYTG), 100% owner of NxGen Brands ("NxGen") d/b/a: LeafyWell.com ("http://www.LeafyWell.com") specializing in CBD products, today announced the execution of a binding letter of intent to acquire Renaissance Health Publishing, LLC. ("Renaissance or the "Company") - A Florida-based company specializing in health and wellness supplements.
Under this agreement, NxGen will acquire 100% of the assets of Renaissance Health Publishing, LLC in cash and stock to complete the acquisition. NxGen will also receive a robust customer base, existing staff and outstanding management team, as well as unique marketing materials and methods designed to advertise the current and existing Renaissance Health Publishing, LLC product lines.
Renaissance is a nationally-known research and development company recognized for its physician-developed, natural health supplements designed to provide health and wellness benefits such as anti-aging, testosterone-boosting, memory-supporting, and libido-boosting effects. Renaissance is perhaps best known for formulating and distributing their own exclusive physician-designed health and wellness supplements manufactured with top-quality ingredients. As a socially-responsible company, they do not perform any animal testing of any kind or at any point during their product research and development. Details on the complete Renaissance product line can be found at RenownHealthProducts.com.
CEO of PYTG, Carlos Hurtado, commented, "We feel that the product lines of Renaissance Health Publishing are of the best on the market and we attribute their incredible success to the quality of the products themselves which have contributed to their long-standing reputation. They have established a numerous customer base and we feel that with this acquisition and the synergy that these products may have with our products at http://www.LeafyWell.com, both our customers and our shareholders will be pleased. It just makes sense - both LeafyWell and Renaissance focus on health and wellness and it is a unique opportunity for us to acquire this company and have the opportunity to increase our customer base - current LeafyWell customers may enjoy the nutraceuticals currently formulated by Renaissance, current Renaissance customers may enjoy the http://www.LeafyWell.com product line, and new customers may enjoy either or both product lines. In our opinion, it is an all-around step in the right direction and we look forward to the effect that this new acquisition would have on our company."
The Letter of Intent from NxGen Brands to acquire Renaissance Health Publishing, LLC is a binding contract and the proposed acquisition is subject only to finalize the execution of a definitive purchase agreement. To that end, the proposed acquisition would be subject to due diligence and audit approvals.
About Pyramidion Technology Group, Inc:
Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company's website at https://pytgcorp.com/.
To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Contact:
info@pytgcorp.com
Phone: +1-954-651-6816
SOURCE Pyramidion Technology Group, Inc.
Gm all
Here we go.... Easy $ this am with the dip.
Indeed wont be long. Once the earnings come out from CBD, booom.
Oh yeah time for money making cheapies.